Клинико-биохимические и иммунологические особенности развития легочной гипертензии при врожденных пороках сердца у детей раннего возраста
Диссертация
Новым направлением в изучении патогенеза многих заболеваний сердца и сосудов (артериальной гипертензии, сахарного диабета, атеросклероза) стало определение роли свободных радикалов. Ткань легких вследствие ее анатомических особенностей и высокого напряжения кислорода наиболее подвержена окислительному стрессу и в норме характеризуется высокой активностью антиоксидантной системы. При… Читать ещё >
Содержание
- Список сокращений
- Глава 1. Обзор литературы
- 1. 1. Клинические особенности, диагностика и лечение легочной гипертензии у детей с врожденными пороками сердца
- 1. 2. Клеточные и молекулярные механизмы в патогенезе 23 легочной гипертензии
- 1. 3. Роль окислительного стресса в развитии легочной 32 гипертензии
- 1. 4. Воспаление в развитии легочной гипертензии
- Глава 2. Материалы и методы исследования
- 2. 1. Объект исследования
- 2. 2. Методы исследования
- 2. 2. 1. Провоспалительные факторы и iNO-синтаза
- 2. 2. 2. Параметры антиоксидантной системы
- 2. 2. 3. Уровень нитритов/нитратов в сыворотке
- 3. 1. Клинико-инструментальное обследование пациентов выделенных групп
- 3. 2. Провоспалительные факторы у детей с ВПС и легочной 66 гипертензией
- 3. 3. Параметры антиоксидантной системы у детей с ВПС и 69 легочной гипертензией
- 3. 4. Показатели системы оксида азота у детей с ВПС и легочной 73 гипертензией
- 3. 5. Анализ корреляций между определявшимися показателями
- I. L Интерлейкин iNOS Индуцибельная NO-синтаза
- V. EGF Сосудистый эндотелиальный фактор роста
- VI. P Вазоактивный интестинальный пептид
Список литературы
- Агапитов Л.И., Белозеров Ю. М. Эндотелийзависимая вазодилатация у детей с легочной гипертензией. Материалы Всероссийского конгресса «Детская кардиология 2004». М., 2004, с. 5.
- Агапитов Л.И., Белозеров Ю. М. Эндотелии и фактор Виллебранда у детей с легочной гипертензией. Материалы Всероссийского конгресса «Детская кардиология 2006″. М., 2006.
- Амбатьелло Л.Г., Чазова И. Е., Масенко В. П. и др. Уровень некоторых маркеров эндотелиальной дисфункции у больных с дефектом межпредсердной перегородки, оперированных в возрасте старше 25 лет. Кардиология, 2001, 41(8):38−42.
- Бакшеев В.И., Коломоец Н. М. Ингибиторы фосфодиэстеразы -реалии и перспективы использования в клинической практике (прошлое, настоящее и будущее силденафила). Клиническая медицина, 2007, 3:4−11, 4:4−11.
- Белозеров Ю. М, Брегель Л. В., Агапитов Л. И. Легочная гипертензия у детей. М., 1998.
- Белозеров Ю.М. Актуальные проблемы легочной гипертензии у детей. Итоги и перспективы научных исследований. Российский вестник перинатологии и педиатрии, 2006, 6:9−12.
- Белозеров Ю.М. Детская кардиология. М., „МЕДпресс-информ“, 2004.
- Белоконь Н.А., Подзолков В. П. Врожденные пороки сердца. М., „Медицина“, 1991.
- Бокерия Л.А. Лекции по сердечно-сосудистой хирургии. Изд.-во НЦССХ им. Н. А. Бакулева, 1999.
- Ю.Бураковский В. И., Бухарин В. А., Плошникова Л. Р. Легочная гипертензия при врожденных пороках сердца. М., 1975.
- И.Вишнякова М. В. Комплексное лучевое исследование детей первогогода жизни с ВПС и сопутствующей патологией легких. Дис.докт.мед. наук, М., 2005.
- Владимиров Ю.А. Свободные радикалы и антиоксиданты. Свободные радикалы и антиоксиданты. Вестн. Росс. акад. мед. наук, 1998, 7:4351.
- И.Горбачев В. И., Введенская JI.C. Нитроксидергическая и тиосульфидная системы организма при легочной гипертензии у детей с врожденными пороками сердца. Terra medica. Лабораторная диагностика, 2005, 1:23−25.
- Горбачевский С.В., Белкина М. В. Обследование больных с врожденными пороками сердца, осложненными легочной гипертензией, в клинике сердечно-сосудистой хирургии. Детские болезни сердца и сосудов, 2006, 3:25−39.
- Давыдовская А.А. Нейрогуморальные механизмы формирования сердечной недостаточности у новорожденных и детей первого года жизни. Автореф. дис.. .канд. мед. наук, М., 2000.
- Жданов А.В., Сосулина Л. Ю., Курбанова Д. Ф. и др. Экспрессия генов цитокинов в мононуклеарных клетках крови у женщин с воспалительными заболеваниями придатков матки. Бюл. экспер. биол. 2002, 134 (11):555−559.
- Иванов С.Н., Старовойтова Е. А., Огородова Л. М., Куликов Е. С. Роль функционального состояния эндотелия в формировании легочной гипертензии у детей. Вопросы современной педиатрии, 2008, т.7, № 1, с.91−95.
- Иродова Н. Л, Ланкин В. З., Коновалова Г. Г., Кочетов А. Г., Чазова И. Е. Окислительный стресс у больных первичной легочной гипертензией. Бюлл. эксп. биол. мед, 2002, июнь, 133(6):580−2.
- Ланкин В.З., Коэнзим Q10: физиологическая функция и перспективы использования в комплексной терапии заболеваний сердечнососудистой системы: пособие для врачей. М.: МЕДПРАКТИКА-М, 2008.
- Леонтьева И.В. Нарушения клеточной энергетики при кардиомиопатиях и возможности применения коэнзима Q10 в лечении. Вестник педиатрической фармакологии и нутрициологии. 2007, Т.4. № 1. С.66−71.
- Мелькумьянц A.M., Балашов С. А. Механочувствительность артериального эндотелия. Тверь, „Триада“, 2005.
- Мутафьян О.А. Врожденные пороки сердца у детей. СПб., „Невский Диалект“, 2002.
- Папаян А.В., Жукова Л. Ю. Анемии у детей: руководство для врачей. Питер- 2001.
- Ройт А., Бростофф Дж., Мейл Д. Иммунология. М., „Мир“, 2000.
- Руководство по детскому питанию. Под ред. В. А. Тутельяна, И. Я. Коня. М., МИА, 2004.
- Смирнов B.C., Кузьмич М. К. Гипоксен (монография). М-Спб, 2001.
- Физиология и патология сердечно-сосудистой системы у детей первого года жизни. Под ред. Школьниковой М. А, Кравцовой Л. А. М., Медпрактика-М, 2002.
- Шарыкин А.С. Врожденные пороки сердца у детей. Руководство для педиатров, акушеров, неонатологов. М., „Теремок“, 2005.
- Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart, 2000, 84: e4.
- Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol, 1993, 54:1−78.
- Aebi H., Methods Enzymol, 1984, 105, 121−126.
- Arend WP. Interleukin-1 receptor antagonist. Adv Immunol, 1993, 54:167 227.
- Asikainen Т. M., К. O. Raivio, M. Saksela, and V. L. Kinnula. Expression and developmental profile of antioxidant enzymes in human lung and liver. Am. J. Respir. Cell Mol. Biol., 1998, 19:942−949.
- Balabanian K, Foussat A, Dorfmuller P, et al. CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 2002- 165: 1419.
- Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006 Apr-l 17(4): 1077−83.
- Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther, 2003, 73:372−382.
- Becker L, Mito T, Takashima S, Onodera K. Growth and developmentof the brain in Down syndrome. Prog Clin Biol Res, 1991, 373:133−52.
- BelAiba RS, Djordjevic T, Bonello S, Fliigel D, Hess J, Kietzmann T, Gorlach A. Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. Biol Chem., 2004, Mar-Apr, 385(3−4):249−57.
- Beutler B, Cerami A. The biology of cachectin/TNF: a primary mediatorof the host response. Ann Rev Immunol, 1989, 7:625−55.
- Black SM, Fineman JR. Oxidative and nitrosative stress in pediatric pulmonary hypertension: Roles of endothelin-1 and nitric oxide. Vascular Pharmacology. 2006, 45:308−316.
- Bloch KD, Ichinose F, Roberts JD, Zapol WM. Inhaled NO as a therapeutic agent. Cardiovascular Research, 2007, 75:339−348.
- Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. PNAS, 2007, 104 (27): 11 418−11 423.
- Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol, 2003, 111:460−75.
- Bowers R, Cool C, Murphy R, Tuder R, Hopken MW, Flores SC, Voelkel NF. Oxidative Stress in Severe Pulmonary Hypertension. Am J Respir Crit Care Med, 2004, Vol.169, pp 764−769.
- Bradbury, Newton R, Zhu YM, Stocks J, Corbett L, Holland ED, Pang LH, Knox AJ. Effect of bradykinin, TGF-P1, IL-lP, and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2002, 283:717.
- Brandes RP, Koddenberg G, Gwinner W, Kim D, Kruse HJ, Busse R, Mugge A. Role of increased production of superoxide anions by NAD (P)Hoxidase and xanthine oxidase in prolonged endotoxemia. Hypertension. 1999, 33:1243−1249.
- Brooksbank BW, Balazs R. Superoxide dismutase, glutathioneperoxidase and lipoperoxidation in Down’s syndrome fetal brain. Brain Res., 1984, 318:37−44.
- Busciglio J, Yankner В A. Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature, 1995, 378:776−9.
- Budhiraja R, Tuder RM, Hassoun PM. Endothelial Dysfunction in Pulmonary Hypertension. Circulation, 2004, 109:159−165.
- Cacoub P, Dorent R, Nataf P et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res, 1997, 33:196−200.
- Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med, 1992, 327:70−5.
- Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest, 2000, 105:21−34.
- Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med, 2000, 6:698−702.
- Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, Pison C. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med., 2001, Sep 15, 164(6): 1038−42.
- Dias-Junior CA, Souza-Costa DC, Zerbini T, da Rocha JB, Gerlach RF, Tanus-Santos JE. The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth Analg., 2005, Jul, 101(1):115−20.
- Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med., 1993,328:106−13.
- Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J, 2003, 22:358−363.
- Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res., 2000, 86:347 354.
- Drummond GR, Dusting GJ, Tan CS, and Sobey SG. Sulphonated aryls are novel selective inhibitors of Nox4-dependent NADPH oxidase activity. FASEB J, Mar 2006- 20: A725.
- Du L, Sullivan CC, Chu D, et al. Signaling molecules in nonfamilialpulmonary hypertension. N Engl J Med, 2003, 348:500−9.
- Ecamot-Laubriet A, Rochette L, Vergely C, Sicard P, Teyssier JR. The activation pattern of the antioxidant enzymes in the right ventricle of rat in response to pressure overload is of heart failure type. Heart Dis., 2003, Sep-Oct, 5(5):308−12.
- Eisenmenger, V. Die Angeboren Defect der Kammer scheiderwand des Herzens. Z Klin Med Suppl, 1897, 32:1.
- Fang YZ, Yang S, Wu G. Free Radicals, Antioxidants, and Nutrition. Nutrition, 2002, Vol.18, P.872- 879.
- Farahmand F, Hill MF, Singal PK. Antioxidant and oxidative stress changes in experimental cor pulmonale. Mol Cell Biochem., 2004, May, 260(l-2):21−9.
- Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M. Chemokine MIP-1 expression in lung biopsies of primary pulmonary hypertension. Chest., 1998, 114:50−51.
- Freidovich I. Fundamental aspects of reactive oxygen species, or what’s the matter with oxygen? Ann NY Acad Sci., 1999, Vol.893, P. 13.
- Fu D, Dai A, Hu R, Chen Y, and Zhu L. Expression and role of factor inhibiting hypoxia-inducible factor-1 in pulmonary arteries of rat with hypoxia-induced hypertension. Acta Biochim Biophys Sin, Oct 2008, 40:883−892.
- Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest., 2000, 105:1631−1639.
- Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. CircRes., 1999, 85:23—28.
- Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med, 1995, 333:214−21.
- Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 1993, 328:1732−9.
- Goldacre MJ, Wotton С J, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down’ssyndrome: a record linkage study. Arch. Dis. Child, 2004, 89: 014−1017.
- Granton GT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart desease. Cardiol Clin, 2002, 20 (2002):441−457.
- Griendling KK, FitzGerald GA. Oxidative Stress and Cardiovascular Injury. Circulation. 2003, 108:1912−1916, 2034−2040.
- Hampl V, Herget J. Role of Nitric Oxide in the Pathogenesis of Chronic Pulmonary Hypertension. Physiol Rev, 2000, 80: 1337−1372.
- Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease. A description of six grades of structural changes in pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958, 18: 533−47.
- Herve' P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med, 1995, 99: 249−54.
- Hickey S. Roberts H. Ascorbate: The Science of Vitamin C, Lulu press, 2004.
- Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. JHypertens. 1992, 10:1379−1386.
- Huang YC, Nozik ES, Piantadosi CA. Superoxide dismutase potentiates platelet-activating factor-induced injury in perfused lung. Am J Physiol. 1994, Mar, 266(3 Pt l):246−54.
- Humpl T, Reyes JT, Holtby H et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation, 2005, 111:3274−3280.
- Ito T, Okada T, Miyashita H, et al. Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats. Circ. Res., Sep 2007- 101: 734 -741.
- Itoh A, Nishihira J, Makita H, Miyamoto K, Yamaguchi E, Nishimura M. Effects of IL-1 beta, TNF-alpha, and macrophage migration inhibitory factor on prostacyclin synthesis in rat pulmonary artery smooth muscle cells. Respirology, 2003, 8(4): 467−72.
- Kaarteenaho-Wiik R and Kinnula VL. Distribution Of Antioxidant Enzymes in Developing Human Lung, Respiratory Distress Syndrome, and Bronchopulmonary Dysplasia. J Histochem Cytochem, 2004, 52:12 311 240.
- Kaneko F.T., Arroliga A.C., Dweik R.A., et al., Am. J. Respir. Crit. Care Med., 1998, 158:917−923.
- Katsushi H, Kazufiimi N, Hideki F, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J, Mar 2004- 68(3): 227−31.
- Kauffman L.D., Sokol R.J., Jones R.H., Awad J.A., Rewers M.J., Norris J.M. Urinary F2-isoprostanes in young healthy children at risk for type 1 diabetes mellitus. Free Radic Biol Med, 2003, 35(6): 551−7.
- Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation, 1997, 95:778−81.
- Kola I, Hertzog PJ. Animal models in the study of the biological function of genes on human chromosome 21 and their role in the pathophysiology of Down syndrome. Human Molecular Genetics, 1997, 6(10): 1713−1727.
- Kowald A and Klipp E. Alternative Pathways Might Mediate Toxicity of High Concentrations of Superoxide Dismutase. Ann. N.Y. Acad. Sci., Jun 2004- 1019: 370−374.
- Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003, 111:1201−1209.
- Lammer AE, Hislop AA, Flynn Y et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart, 2007, 93(6): 739−743.
- Launay JM, Herve' P, Peoc’h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med, 2002, 8:1129−35.
- Li WG, Miller FJ, Jr., Zhang HJ, Spitz DR, Oberley LW, Weintraub NL. H (2)0(2)-induced 0(2) production by a non-phagocytic NAD (P)H oxidase causes oxidant injury. J Biol Chem., 2001, 276:29 251−29 256.
- Limsuwan A, Platoshyn O, Yu Y, Rubin LJ, et al. Inhibition of K1 Channel Activity in HumanPulmonary Artery Smooth Muscle Cells by Serum from Patients with Pulmonary Hypertension Secondary to Congenital Heart Disease. Pediatr Res, 2001, 50:23−28.
- Liu JQ, Folz RJ. Extracellular superoxide enhances 5-HT-induced murine pulmonary artery vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2004, Jul, 287(1):111−8.
- MacLean MR, Herve' P, Eddahibi S, Adnot S. 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol, 2000, 131:161−8.
- Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart, 2006, 92:664−670.
- McCarthy K, Bhogal M, Nardi M, et al. Pathogenic factors of broncho-pulmonary dysplasia. Pediatr Res, 1984, 18:483−487.
- Mclntyre M, Bohr DF, Dominiczak AF. Endothelial Function in Hypertension: The Role of Superoxide Anion. Hypertension, 1999, 34:539 -545.
- McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED. Dichloroacetate prevents and reverses pulmonaryhypertension by inducing pulmonary artery smooth muscle cell apoptosis. Cirs. Res., 2004, 95:830−840.
- Meilhac O, Zhou M, Santanam N, Parthasarathy S. Lipid peroxides induce expression of catalase in cultured vascular cells. J Lipid Res., 2000, 41:1205−1213.
- Michelakis ED, Tymchak W, Noga M, et al. Long-term treatmentwith oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation, 2003,108:2066−9.
- Miles MV, Patterson В J, Chalfonte-Evans ML, Horn PS, Hickey FJ, Schapiro MB, Steele PE, Tang PH, Hotze SL. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol. 2007 Dec-37(6):398−403.
- Miranda K.M., Espey M.G., Wink D.A., NITRIC OXIDE: a rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Biology and Chemistry, 2001, 5:62−71.
- Molet S, Furukawa K, Maghazechi A, Hamid Q, and Giaid A. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells. J Allergy Clin Immunol, Feb 2000- 105(2 Pt 1): 333−8.
- Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J, 2004, 18:1791−1800.
- Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-Hydroxytryptamine receptors mediating contraction in hmnan small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol, 1999, 128:730−4.
- Muller DPR. Free radical problems of the newborn. Proc Nutr Soc, 1987, 46:69−75.
- Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006 Nov l-174(9):1042−7.
- Pallardo FV, Degan P et al. Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology, 2006, 7(4): 211−20.
- Park MK. Pediatric Cardiology. 5th ed. MOSBY Elsevier, 2008.
- Park YS, Fujiwara N, Koh YH, Miyamoto Y, Suzuki К, Honke K, Taniguchi N. Induction of thioredoxin reductase gene expression by peroxynitrite in human umbilical vein endothelial cells. Biol Chem., 2002, 383:683−691.
- Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest, 2003, 111:1339−46.
- Popov I.N., Lewin G., Free Radic Biol Med, 1994, 17:267−271.
- Rabinovitch, M, Haworth, SG, Castaneda, AR, et al. Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease. Circulation, 1978, 58:1107.
- Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest, 1998, 114:213−24.
- Robbins IM, Morrow JD, Christman BW. Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med., 2005, Mar, 1, 38(5):568−74.
- Roberts LJ, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med, 2000, 28(4):505−513.
- Romero N., Radi R, Linares E., et al. Biol.Chem., 2003, 278, 4 404 944 057.
- Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol, 1996, 28: 803−812.
- Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation, 1999, 99:1858−65.
- Rudge JS, Thurston G, Yancopoulos GD. Angiopoietin-1 and pulmonary hypertension: cause or cure? Circ Res, 2003, 92:947−9.
- Semenza GL. 02-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-l. J Appl Physiol, Mar 2004, 96:1173−1177.
- Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling ЮС. Angiotensin II stimulation of NAD (P)H oxidase activity: upstream mediators. Circ Res., 2002, 91:406−413.
- Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med., 1999, Vol.27, P.916.
- Simonneau G, Galie» N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol, 2004, 43:5−12.
- Sinet PM. Metabolismof oxygenderivatives inDown’ssyndrome. AnnN Y Acad Sci, 1982, 396:83−94.
- Souza-Costa DC, Zerbini T, Metzger IF, Rocha JB, Gerlach RF, Tanus-Santos JE. 1-Arginine attenuates acute pulmonary embolism-induced oxidative stress and pulmonary hypertension. Nitric Oxide. 2005, Feb, 12(1):9−14.
- Stralin P, Marklund SL. Vasoactive factors and growth factors alter vascular smooth muscle cell EC-SOD expression. Am J Physiol Heart Circ Physiol. 2001, 281:1621−1629.
- Sullivan CC, Du L, Chu D, et al. Induction of pulmonary hypertension by an angiopoietin l/TIE2/serotonin pathway. Pro с Natl Acad Sci U S A 2003−100:12 331−6.
- Touyz RM and Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol, 2004, 122:339−352.
- Tsukahara H. Biomarkers for Oxidative Stress: Clinical Application in Pediatric Medicine. Current Medicinal Chemistry, 2007, 14, 339−351.
- Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med, 1999, 159:1925−32.
- Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol, 2001, 195:367−74.
- Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol, 2006, 290:209 221.
- Vuttariello E, Pagano G. Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology, 2006, 7(4): 211−20.
- Wassmann S, Wassmann K, Nickenig G. Modulation of Oxidant and Antioxidant Enzyme Expression and Function in Vascular Cells Hypertension. 2004, 44:381−386.
- Wedgwood S and Black SM. Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension. Antioxid Redox Signal, 2003, 5:759−769.
- Weir EK, Reeve HL, Huang JMC, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation, 1996, 94:2216−20.
- Wispe JR, Bell EF, Robers RJ. Assessment lipid peroxidation in newborn infants and rabbits by measurements of expired ethane and pentane: influence of parenteral lipid infusion. Pediatr Res, 1985, 19:374 379.
- Yuan JX, Wang J, Juhaszova M, Gaine SP, Rubin LJ. Attenuated Kchannel gene transcription in primary pulmonary hypertension. Lancet, 1998,351:726−7.
- Zana M, Szecsenyi A, Czibula A et al. Age-dependent oxidative stress-induced DNA damage in Down’s lymphocytes. Biochem Biophys Res Commun, 2006, June 30, 345(2):726−33.